Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole, Lapatinib, and Everolimus in Endocrine-Resistant Breast Cancer
NCT01499160Phase 2Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- May 2012
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in breast cancer, sponsored by University of Maryland, Baltimore. Primary endpoint: Clinical Benefit Rate at 24 months. Started May 2012; status: terminated.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01499160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01499160.